appScorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Lincoln Pharmaceuticals Ltd
LINCOLN
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Dr Reddy's Laboratories Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Lincoln Pharma Standalone December 2022 Net Sales at Rs 133.77 crore, up 11.58% Y-o-Y
2 weeks ago•Moneycontrol
Lincoln Pharmaceuticals consolidated net profit rises 22.78% in the December 2022 quarter
1 month ago•Business Standard
Recent EventsAll events
Disclosure under SEBI Takeover Regulations
Hansaben Arvindbhai Patel has submitted toￂﾠ the Exchange a copy of Disclosure under Regulation 10(6)-Report to stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in regulation 10 of SEBI (SAST) Regulations, 2011. | Download
Hansaben Arvindbhai Patel has submitted toￂﾠ the Exchange a copy of Disclosure under Regulation 10(6)-Report to stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in regulation 10 of SEBI (SAST) Regulations, 2011. | Download
Disclosure under SEBI Takeover Regulations
Manguben Ishwarlal Patel has submitted toￂﾠ the Exchange a copy of Disclosure under Regulation 10(6)-Report to stock exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (SAST) Regulations, 2011. | Download
Manguben Ishwarlal Patel has submitted toￂﾠ the Exchange a copy of Disclosure under Regulation 10(6)-Report to stock exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (SAST) Regulations, 2011. | Download
Cash Dividend
Final • Div/Share: ₹ 1.5
Increased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 2.25%